HRP20210561T1 - Mjesta za vezanje antitijela specifičnih za egfrviii - Google Patents

Mjesta za vezanje antitijela specifičnih za egfrviii Download PDF

Info

Publication number
HRP20210561T1
HRP20210561T1 HRP20210561TT HRP20210561T HRP20210561T1 HR P20210561 T1 HRP20210561 T1 HR P20210561T1 HR P20210561T T HRP20210561T T HR P20210561TT HR P20210561 T HRP20210561 T HR P20210561T HR P20210561 T1 HRP20210561 T1 HR P20210561T1
Authority
HR
Croatia
Prior art keywords
amino acid
acid sequence
seq
sequence according
egfrviii
Prior art date
Application number
HRP20210561TT
Other languages
English (en)
Croatian (hr)
Inventor
Kristina Ellwanger
Uwe Reusch
Ivica FUCEK
Stefan Knackmuss
Vera MOLKENTHIN
Melvyn Little
Eugene Zhukovsky
Original Assignee
Affimed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Gmbh filed Critical Affimed Gmbh
Publication of HRP20210561T1 publication Critical patent/HRP20210561T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20210561TT 2013-08-07 2014-08-07 Mjesta za vezanje antitijela specifičnih za egfrviii HRP20210561T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13179630 2013-08-07
EP13189599 2013-10-21
EP14758087.2A EP3030581B1 (en) 2013-08-07 2014-08-07 Antibody binding sites specific for egfrviii
PCT/EP2014/002177 WO2015018527A1 (en) 2013-08-07 2014-08-07 ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII

Publications (1)

Publication Number Publication Date
HRP20210561T1 true HRP20210561T1 (hr) 2021-05-14

Family

ID=51453717

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210561TT HRP20210561T1 (hr) 2013-08-07 2014-08-07 Mjesta za vezanje antitijela specifičnih za egfrviii

Country Status (13)

Country Link
US (1) US10273309B2 (OSRAM)
EP (1) EP3030581B1 (OSRAM)
JP (1) JP6529498B2 (OSRAM)
CN (1) CN105555804B (OSRAM)
AU (1) AU2014304930B2 (OSRAM)
CA (1) CA2920173C (OSRAM)
DK (1) DK3030581T3 (OSRAM)
HR (1) HRP20210561T1 (OSRAM)
HU (1) HUE054057T2 (OSRAM)
LT (1) LT3030581T (OSRAM)
RU (1) RU2696892C2 (OSRAM)
SI (1) SI3030581T1 (OSRAM)
WO (1) WO2015018527A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102399005B1 (ko) 2014-03-11 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 항-egfrviii 항체 및 그것의 용도
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
EP2982693A1 (en) 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
JP6616833B2 (ja) * 2014-11-25 2019-12-04 ファームアブシン インコーポレイテッド 新規ＥＧＦＲｖＩＩＩ抗体及びこれを含む組成物
JP2018516248A (ja) 2015-05-29 2018-06-21 アンフィヴェナ セラピューティクス，インク． 二重特異性のｃｄ３３およびｃｄ３結合タンパク質を使用する方法
EP3307319A4 (en) * 2015-06-09 2019-05-22 Memorial Sloan Kettering Cancer Center T CELL RECEPTOR-SIMILAR ANTIBODIES SPECIFIC TO PEPTID OF THE LATENT EBV MEMBRANE PROTEIN 2A PRESENTED BY HUMAN HLA
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) * 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
US10221242B2 (en) 2016-01-21 2019-03-05 Pfizer Inc. Antibodies specific for epidermal growth factor receptor variant III and their uses
ES2942362T3 (es) 2016-01-21 2023-05-31 Pfizer Receptores quiméricos para el antígeno que se dirigen a la variante III del receptor del factor de crecimiento epidérmico
IL260920B (en) 2016-02-03 2022-09-01 Amgen Res Munich Gmbh Constructs of psma and cd3 bispecific antigens that bind to t-cells, preparations containing them and uses thereof
CN107556386A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用
RU2725950C1 (ru) * 2016-08-05 2020-07-07 И-Байолоджикс Инк. Антитела против белка-1 запрограммированной клеточной смерти (pd-1) и их применение
CA3032806C (en) * 2016-08-05 2021-04-27 Y-Biologics Inc. Antibody to programmed death-ligand 1 (pd-l1) and use thereof
CN106501518A (zh) * 2017-01-06 2017-03-15 北京弘润天源生物技术股份有限公司 一种检测EGFRvⅢ的免疫组化抗体试剂及检测方法
AU2018228719B2 (en) * 2017-02-28 2023-03-30 Affimed Gmbh Tandem diabody for CD16A-directed NK-cell engagement
CA3089287A1 (en) 2018-02-08 2019-08-15 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
JP7288913B2 (ja) * 2018-03-14 2023-06-08 アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク 二重特異性ｅｇｆｒ／ｃｄ１６抗原結合タンパク質
MX2021007307A (es) * 2018-12-21 2021-07-07 Hoffmann La Roche Anticuerpos que se unen a cd3.
KR20210116478A (ko) * 2019-01-14 2021-09-27 난징 레전드 바이오테크 씨오., 엘티디. 키메라 수용체 폴리펩티드 및 이의 용도
AR120741A1 (es) 2019-12-13 2022-03-16 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso
EP4154910A4 (en) * 2020-06-30 2024-09-11 Harbour Biomed (Shanghai) Co., Ltd Binding protein having h2l2 and hcab structures
WO2022159685A2 (en) * 2021-01-22 2022-07-28 Vanderbilt University Sars-cov-2 coronavirus antibodies and uses thereof
AU2022273541A1 (en) 2021-05-14 2023-11-30 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
WO2023287941A2 (en) * 2021-07-16 2023-01-19 Medical Guidance Systems, Llc Anti-tax interacting protein-1 (tip1) binding molecules
WO2023125729A1 (zh) * 2021-12-31 2023-07-06 康源博创生物科技(北京)有限公司 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用
WO2024258870A2 (en) 2023-06-12 2024-12-19 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19819846B4 (de) * 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
HUP0204142A3 (en) * 2000-02-25 2004-12-28 Univ Durham Anti-egfrviii scfv-antibodies with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
CN104059147A (zh) * 2003-06-27 2014-09-24 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用

Also Published As

Publication number Publication date
JP2016536322A (ja) 2016-11-24
AU2014304930A1 (en) 2016-02-25
CN105555804A (zh) 2016-05-04
EP3030581A1 (en) 2016-06-15
CN105555804B (zh) 2020-12-25
DK3030581T3 (da) 2021-04-12
HUE054057T2 (hu) 2021-08-30
BR112016002610A8 (pt) 2018-01-23
US10273309B2 (en) 2019-04-30
SI3030581T1 (sl) 2021-07-30
US20160152728A1 (en) 2016-06-02
WO2015018527A1 (en) 2015-02-12
HK1218552A1 (zh) 2017-02-24
CA2920173A1 (en) 2015-02-12
BR112016002610A2 (pt) 2017-09-12
RU2016106577A (ru) 2017-09-14
CA2920173C (en) 2021-08-10
AU2014304930B2 (en) 2019-11-21
RU2696892C2 (ru) 2019-08-07
JP6529498B2 (ja) 2019-06-12
EP3030581B1 (en) 2021-01-20
LT3030581T (lt) 2021-05-25

Similar Documents

Publication Publication Date Title
HRP20210561T1 (hr) Mjesta za vezanje antitijela specifičnih za egfrviii
JP2016536322A5 (OSRAM)
HRP20170882T1 (hr) Humani antigen-vezujući proteini koji se vežu za beta-klotho, fgf receptore i njihove komplekse
NZ750366A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
HRP20200679T1 (hr) Molekule koje vežu antigen i sadrže trimer tnf ligand obitelji
HRP20140258T1 (hr) Bispecifiäśni proteini koji se vežu na antigene
EA200800696A1 (ru) Полипептиды и антитела
JP2019525738A5 (OSRAM)
HRP20201156T1 (hr) Zajednički laki lanci i postupci primjene
HRP20140727T1 (hr) Bivalentna, bispecifiäśna protutijela
RU2015129813A (ru) Антитела, которые связываются с лигандом запрограммированной клеточной смерти 1 (pd-l1)
HRP20130877T1 (hr) Antitijela koja neutraliziraju humani citomegalovirus i njihova primjena
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
HRP20241469T1 (hr) Poboljšana veziva albumina u serumu
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
MY200988A (en) CD3 Binding Antibodies
HRP20180269T1 (hr) Anti-cd40 protutijela, upotrebe i postupci
HRP20201517T1 (hr) Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123
JP2015508757A5 (OSRAM)
CL2010000096A1 (es) Anticuerpo monoclonal o una porción que se une al antígeno del mismo que se une a alk-1, molécula de acido nucleico codificante; composición farmaceutica que lo comprende; uso de dicho anticuerpo para preparar un medicamento útil para inhibir la angiogénesis en un mamifero. (div.sol.2333-06).
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
HRP20220649T1 (hr) Novi bispecifični format pogodan za upotrebu u visokopropusnom skriningu
RU2013110876A (ru) Активируемые биспецифические антитела
HRP20191590T1 (hr) Protutijela za bubrežni antigen 1 i njihov fragment koji veže antigen
CO6280541A2 (es) Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40